Clinical Trial Search

Primary: Change in Static Balance as Recorded Using Dynamic Posturography With the Sensory Organization Test (SOT 1-3) — -3.25; 2.05; 1.78 units on a scale — p=0.699

Primary: Number of Confabulations — 30.0; 29.9; 8.1; 35.5 Confabulations

Primary: Mean Radiation Dermatitis Severity Score — 2.02; 1.99 units on a scale — p=0.6555

Primary: Pharmacokinetics: Maximum Concentration (Cmax) of Dulaglutide — 29.4; 44.2; 81.5; 20.7 nanograms per milliliter (ng/mL)

Primary: Epithelial Healing After Laser Assisted in Situ Keratomileusis (LASIK) Surgery — 4.3; 3.5; 9.2; 9.0 Clock Hours

Primary: Visit 1: Percent Change in Core Body Temperature — -1.2; 0.05 Percent Change — p=<0.01

Primary: Estimated Area Under the Liver Concentration-time Curve for 24 Hours Post-dose (AUC[H]0-24hr) of Grazoprevir — 19800 µM*hr

Primary: Area Under the Concentration-time Curve From 0 to 24 Hours Postdose (AUC0-24hr) of Grazoprevir — 0.969; NA; NA; 0.944 uM*hr

Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12) — 96.3 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12) — 85.2; 75.0; 94.1; 76.9 percentage of participants

Primary: GI Mucosal Lesions Change and Clinical Symptoms Using The Gastrointestinal Symptom Rating Scale (GSRS) Score — 2.99; 2.19 GSRS score — p=0.05

Primary: Number of Participants With Treatment Completion Rate (TCR) — 9; 10; 4; 5 participants

Primary: Percentage of Participants With Adverse Drug Reactions (ADRs), Toxicities, Avastin-Related ADRs, and Serious ADRs — 88.6; 88.2; 27.0; 11.1 percentage of participants

Primary: Brief Psychiatric Rating Scale (BPRS) Total Score — 44.1; 44.3 units on a scale

Primary: Objective Response Rate (ORR) by Investigator — 12; 14 percentage of participants